Business Wire

STRONGPOINT

23.6.2021 08:02:07 CEST | Business Wire | Press release

Share
StrongPoint’s Order Picking Solution Delivers Unprecedented Levels of Efficiency to Accelerate Grocers’ E-Commerce Capabilities

StrongPoint ASA , a leading European grocery retail solution provider, today announces its grocery e-commerce picking solution, designed specifically for grocery retailers looking for fast, hyper-efficient and scalable e-commerce logistics solutions. The Strongpoint solution suite delivers industry-leading efficiency rates with many in-store associates averaging ~240 items picked per labor hour across all product categories, compared with common industry standards of 60-65 items per hour.

Hosted on StrongPoint’s cloud-based SaaS e-commerce platform, the Order Picking solution helps retailers capitalize on the growing opportunity of online grocery, driving greater efficiency and higher productivity rates. It also reduces labor costs associated with the fulfillment of online orders, while enhancing customer convenience and protecting margins.

StrongPoint launched its first Order Picking solution more than 20 years ago. Since then, it has undergone countless iterations, changes and updates based on customer feedback over two decades of usage by thousands of pickers in multiple countries. A key benefit of StrongPoint’s cloud-based solution is that grocery retailers receive continuous updates as the team finds new opportunities to drive efficiency gains.

Since the start of the pandemic, Bain estimates adoption of online grocery in the US and Western Europe has accelerated between two and five years and this sustained demand is set to continue2 . Despite the explosion in demand, both for grocery e-commerce and q-commerce, retailers have struggled to make online grocery profitable, with the high cost of labor hours allocated to picking and the fulfillment of e-commerce orders ebbing away at already squeezed margins.

StrongPoint’s solution was born out of 35+ years’ experience in responding to the rapidly evolving needs of leading grocery retailers across multiple European countries. Its grocery e-commerce Order Picking solution delivers unprecedented efficiencies compared to orders that are picked manually, by empowering staff with its proprietary software technology.

Many of StrongPoint’s grocery retail customers who are utilizing the full functionalities of the solution are able to reach average in-store picking rates of ~240 items per labor hour across all product categories, compared with a common industry standard of 60-65 items per labor hour when using traditional solutions. In addition, StrongPoint’s Order Picking solution averages 99.99% accuracy, making it on par with leading fully automated grocery fulfillment solutions.

Its hyper-efficient orchestration technology customizes the picking route for the store associate, creating the most effective order sequencing for picking, based on the unique layout and footprint of each store. Other standard features include picking by temperature zones, multiple solutions for age-restricted items and substitution options.

The solution, which can be deployed in large and small format settings with the option of using Zebra hardware devices for maximum efficiency, includes multi-zone and multi-order picking capabilities to drive even greater efficiencies. It can integrate with in-built store hardware, such as electronic shelf labels (ESLs), allowing store associates to “pick to light” to increase speed and order accuracy. In addition, there is the option of integrating a smart trolley that has been purpose-built for maximum ergonomic efficiency. Data inputs at each stage of the picking process – from preparing the trolley to the picking, weighing, and bagging of products – create a continuous feedback loop, so ergonomic improvements can be made to drive further efficiencies, speed and accuracy.

“We are proud to unveil our latest technology solution, specifically designed to help grocery retailers leverage their stores and cater to the exponential growth of e-commerce,” said Jacob Tveraabak, CEO at StrongPoint. “Having worked with grocery retailers for over three decades, we understand the importance of driving speed, efficiency and scalability across their operations in the stores – and that was intrinsic in how we developed the latest iteration of our grocery e-commerce Order Picking solution.”

-ENDS-

Notes to editors

StrongPoint is a retail technology company that provides solutions to make shops smarter, shopping experiences better and online grocery shopping more efficient.

With over 450 employees in Norway, Sweden, the Baltics and Spain and, together with a wide partner network, StrongPoint supports businesses in more than 20 countries.

StrongPoint is headquartered in Norway and is listed on the Oslo Stock Exchange.

For more information, visit https://www.strongpoint.com/


1 https://www.mwpvl.com/MWPVL_International_-_Micro_Fulfillment_Centers_-_Passing_Fad_or_Permanent_Market_Shift.pdf
2 https://www.bain.com/insights/the-next-five-years-in-online-grocery-snap-chart/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye